No-Myeloablative Conditioning Regimen Cyclosphophamide-Fludarabine-ATG (Cy-Flu-ATG) Results in Better Overall Survival Compared with Myeloablative Doses of Cy with or without ATG, in High-Risk Bone Marrow Failure Syndromes (BMFS) Patients